Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mIBI in patients with hepatocellular carcinoma

Leung Li¹
Stephen L Chan¹
Frankie Mo¹
Edwin P Hui¹
Jane Koh¹
Allen KC Chan²
Nelson LS Tang²
Kit F Lee³
Paul BS Lai³
Simon CH Yu⁴
Winnie Yeo¹

¹Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong SAR; ²Department of Chemical Pathology, Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR; ³Department of Surgery, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR; ⁴Department of Diagnostic and Interventional Radiology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR

Correspondence: Winnie Yeo
Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong SAR
Tel +86 852 3505 2118
Fax +86 852 2648 7097
Email winniedyeo@cuhk.edu.hk

Purpose: Health-related quality of life (HRQoL) is a significant prognostic factor for overall survival in hepatocellular carcinoma (HCC) patients, and this is independent of stage and liver function. Inflammation plays a significant role in HCC development and progression. It was hypothesized that the inflammatory status of HCC patients may affect their HRQoL. The relationship between HRQoL and inflammatory status was explored using indicators IL-8 level and modified inflammation-based index (mIBI, based on IL-8, C-reactive protein, and albumin).

Methods: From 2007–2011, HCC patients were enrolled prospectively. Baseline HRQoL assessment utilized the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-HCC18; clinical and laboratory data were collected at diagnosis. Two summary indices, C30 and HCC18 index-scores, were calculated. Correlation analyses were performed between HRQoL and inflammatory markers.

Results: In the 445 patients studied, significant correlations were found between IL-8 levels and EORTC QLQ-C30, QLQ-HCC18, C30, and HCC18 index-scores. The strongest correlated factors were those reflective of constitutional symptoms, namely QLQ-C30 “appetite loss” (with Pearson’s correlation coefficient, r=0.322, P<0.0001); QLQ-C30 “fatigue” (r=0.311, P<0.0001); QLQ-C30 “role functioning” (r=−0.305, P<0.0001); QLQ-HCC18 “nutrition” (r=0.317, P<0.0001); and QLQ-HCC18 “fatigue” (r=0.306, P<0.0001). In addition, moderate but significant correlations were also observed with HCC18 index score (r=0.321, P<0.0001), and C30 index score (r=0.306, P<0.0001). HRQoL factors were also significantly correlated with mIBI.

Conclusion: Baseline HRQoL using the conventional assessments of EORTC QLQ-C30 and QLQ-HCC18, as well as C30 and HCC18 index-scores, significantly correlated with inflammatory indicators (IL-8 level and mIBI) in HCC patients. Among the strongest correlations were those between IL-8 level and the two index-scores, as well as HRQoL aspects that represent constitutional symptoms. When paralleled with molecular findings, traditional HRQoL assessment in HCC has gained a new level of understanding: pattern recognition within an HRQoL instrument could potentially identify patients with more severe inflammatory state.

Keywords: cytokine interleukin 8, index score, EORTC QLQ-C30, EORTC QLQ-HCC18, liver cancer, modified inflammation-based index

Introduction

Hepatocellular carcinoma (HCC) is an aggressive cancer, which carries a high morbidity and mortality. It is the fifth commonest cancer and the second leading cause of cancer death in the world.¹ In early days, when HCC treatment was limited, the
Inflammation plays a significant role in HCC development and progression. In HCC, an immunosuppressive environment has been demonstrated. Tumor-promoting inflammatory cells, including myeloid-derived suppressive cells (MDSC) and regulatory T cells, and tumor-promoting microenvironment have been reported to foster cancer cells immune evasion, proliferation, invasiveness, and angiogenesis. Predominant Th2-like cytokines (IL-4, IL-8, IL-10, and IL-5) compared to Th1-like cytokines (IL-1α, IL-1β, IL-2, tumor necrosis factor α) in the tumor microenvironment was associated with a more aggressive form of HCC.

HCC patients with higher MDSC counts were found to have higher serum IL-10, IL-13, and vascular endothelial growth factor levels. These patients have been reported to have more advanced stage HCC, poorer liver functional reserve, and shorter overall survival (OS). On the contrary, HCC patients with an inflammatory microenvironment with the presence of immune cells infiltration and an expression of innate immune response genes within their resected tumors were shown to have more favorable prognosis with longer survival than those without such an inflammatory microenvironment.

It is unknown if tumor-promoting or tumor-inhibitory inflammatory responses would result in systemic manifestation along with elevation in inflammatory markers including serum cytokine levels, thereby affecting patients' constitutional symptoms. For instance, a higher serum IL-6 level has been associated with shorter survival in one study; however, another study has reported conflicting results. On the other hand, higher serum levels of IL-8, IL-35, fibroblast growth factor 2, growth-regulated oncogene, interferon gamma-induced protein 10, vascular endothelial growth factor, as well as lower serum levels of interferon alpha-2 have also been reported to be associated with shorter relapse-free and OS in HCC patients. Various studies have explored the prognostic significance of a panel of cytokines in HCC patients, one of these studies was from our group, who evaluated 42 cytokines. IL-8 has been consistently found to be the only significant prognostic cytokine for survival.

HRQoL is a multifaceted and complex assessment of human life with special attention paid to healthcare-related issues. Earlier reports, as well as more recent studies, have shown HRQoL to be a prognostic factor for patients with early as well as advanced stage HCC. The incorporation of HRQoL data into existing staging systems has been suggested to further enhance their prognostication powers. In our recently reported cohort, the prognostic significance of baseline HRQoL at HCC presentation was independent of clinical variables including the stage of HCC, liver function, and patient's demographic data. The HRQoL factors that were analyzed included a general HRQoL instrument for cancer patients, the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, as well as HCC-specific HRQoL instrument, QLQ-HCC18. Apart from conventional assessment using these instruments, our proposed C30 index score and HCC18 index score, which were, respectively, summative scores of all the domains and items of QLQ-C30 and QLQ-HCC18, were also found to be significant prognosticators. These index scores have the advantage of transforming complex HRQoL data into simpler tools that are applicable to routine daily clinical practice.

A few recent reports have suggested that correlations exist between HRQoL and cytokine levels in patients with advanced malignancies. Although the reason for such a correlation has not yet been elucidated, cancer-induced cytokine release as a result of inflammatory response has been implicated in cachexia. Alongside functional impairment, cachexia is associated with a variety of symptoms including malaise, anorexia, and weight loss. We hypothesized that HRQoL impairment in HCC patients may be correlated with their status of inflammation. In this study among HCC patients, the objectives were to determine the correlations between HRQoL and inflammatory status of individual patients. The latter was determined by IL-8 level and the modified inflammation-based index (mIBI), which have recently been identified to be prognostic markers in patients with HCC.

**Methods**

**Patients**

From January 2007 to December 2011, newly diagnosed HCC patients were invited to the study.

Patients were eligible for the study if they had newly diagnosed HCC (based either on histology, typical findings from radiological and biochemical tests, or typical imaging findings in two radiological modalities), had not received any treatment for HCC, and were able to read and comprehend Chinese. Patients were excluded from the study if they had a history of other malignancies, encephalopathy, or cognitive impairment.
HRQoL assessment

Individual patients completed HRQoL assessment at study entry using self-administered EORTC QLQ-C30 and QLQ-HCC18 questionnaires (Chinese versions). C30 and HCC18 index-scores were calculated as previously published. Detailed descriptions of these assessments are listed in Table 1.

Inflammatory markers, clinical factors, and follow-up

Baseline blood taken was used to assess the serum levels of IL-8, C-reactive protein (CRP), and albumin. mIBI is an inflammation-based score derived from IL-8, CRP, and albumin levels. To calculate mIBI, a score is assigned according to the level of log_{10} IL-8 (0 for <1.8; 1 for ≥1.8), CRP (0 for <10 mg/dL; 1 for ≥10 mg/dL), and albumin (0 for ≥35 g/L; 1 for <35 g/L), respectively. mIBI score is the summation of these three scores. The cut-off of log_{10} IL-8 at 1.8 was determined by a receiver operator characteristic curve in the prognostic analysis, which has been reported previously. Demographic and clinical data were collected. Patients were followed up until death.

Statistical analyses

Patient characteristics were assessed by standard descriptive analyses. Correlation between continuous variable (log IL-8 level) and continuous HRQoL factors was analyzed using Pearson’s correlation analysis. Patients were dichotomized into mIBI scores of 2–3 vs 0–1 and into log IL8 of ≥1.8 vs <1.8 for correlative analyses. Correlations between the dichotomized variables and continuous HRQoL factors were analyzed by Student’s t-test and/or logistic regressions. The statistical analyses were performed using statistical software (SAS version 9.3; SAS Institute, Cary, NC). A P-value of <0.05 was regarded as statistically significant.

Ethics approval and informed consents

This study was approved by the regional ethics committee (Joint Clinical Research Ethics Committee of the Chinese University of Hong Kong and New Territories East Cluster of Hospital Authority). Written informed consent was obtained from all study patients.

Results

Patient characteristics

Four hundred and forty-five patients had complete HRQoL data and information on their inflammatory indicators. Tables 2 and 3 show the patients’ baseline clinical characteristics, inflammatory indicators, and HRQoL. The median age at diagnosis was 60 years. The majority of patients (94%) had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Fifty-eight percent had hepatitis B, while 6% had hepatitis C infection. Fourteen percent belonged to Barcelona Clinic Liver Cancer (BCLC) stage A, 24% stage B, 56% stage C, and 5% stage D. With regards to first-line treatment, 51 patients (12%) had surgery, 28 (6%) had local ablative therapy, 110 (25%) had trans-arterial therapy. Table 1

Table 1 HRQoL instruments used in the study.

| EORTC QLQ-C30 | EORTC QLQ-C30 is a general cancer instrument containing multiple items, measured in multiple-point Likert scales, that reflects the multidimensionality of the HRQoL construct. It includes five functional domains (physical, role, cognitive, emotional, and social), three symptom domains (fatigue, pain, and nausea and vomiting), and a global health and HRQoL domain. Six single items assess common symptoms in cancer patients (dyspnea, appetite loss, sleep disturbance, constipation, diarrhea), and financial problems. All scales and domains are transformed to scores ranging from 0–100. A lower score for a functional or global HRQoL scale reflects a poorer functioning level or global QoL, while a lower score for a symptom/problem scale reflects less symptoms/problem (better HRQoL). |
| EORTC QLQ-HCC18 | EORTC QLQ-HCC18 includes 18 multiple item scales organized into six domains (fatigue, body image, jaundice, nutrition, pain, and fever) and two items (abdominal swelling and sex life). All scales are grouped and transformed to score ranging from 0–100. A lower score represents a less severe symptom/problem (better HRQoL). EORTC QLQ-HCC18 is used together with EORTC QLQ-C30. |
| C30 index score | \( \sum \) [(100-physical functioning), (100-role functioning), (100-emotional functioning), (100-cognitive functioning), (100-social functioning), (100-global QoL), scores of fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhea, financial difficulty] + 15 \nRange of C30 index score: 0–100; a lower score represents a less severe symptom/problem. |
| HCC18 index score | \( \sum \) (scores of fatigue, body image, jaundice, nutrition, pain, fever, sex life, abdominal distension) + 8 \nRange of HCC18 index score: 0–100; a lower score represents a less severe symptom/problem. |

Abbreviations: EORTC, European Organization for Research and Treatment of Cancer; HCC, Hepatocellular carcinomas; HRQoL, health-related quality of life.
Table 2 Baseline clinical and laboratory characteristics of HCC patients.

| Factors                          | No. (%) | Median (range) |
|---------------------------------|---------|----------------|
| Age (years)                     | 445     | 60 (18–88)     |
| Gender                          |         |                |
| Male                            | 395 (88.8) |              |
| Female                          | 50 (11.2) |                |
| ECOG performance status         |         |                |
| 0                               | 137 (30.8) |              |
| 1                               | 283 (63.6) |              |
| 2                               | 18 (4.0) |                |
| 3                               | 7 (1.6) |                |
| Baseline biochemistry           |         |                |
| Bilirubin (µmol/L, range)       | 19 (3–548) |              |
| Albumin (g/L)                   | 37 (8–53) |                |
| ALT (iu/L)                      | 57 (12–564) |             |
| Prothrombin time (s)            | 12.3 (8.9–32.9) |        |
| AFP (ng/mL)                     | 239 (1–3,637,000) |       |
| Hepatitis B, %                  | 361 (81.1) |              |
| Hepatitis C, %                  | 29 (6.5) |                |
| Cirrhosis, %                    | 260 (58.4) |             |
| Ascertes                        | 111 (24.9) |            |
| Vascular Involvement            | 144 (32.4) |            |
| Tumor number (Single : Multiple) | 165 : 280 |            |
| Child-Pugh Class A              | 303 (68.1) |            |
| B                               | 125 (28.1) |            |
| C                               | 17 (3.8) |                |
| AJCC stage                      |         |                |
| I                               | 17 (3.8) |                |
| II                              | 112 (23.1) |             |
| III                             | 57 (12.9) |                |
| IV                              | 259 (58.2) |             |
| Okuda stage                     |         |                |
| I                               | 203 (45.6) |            |
| II                              | 202 (45.4) |            |
| III                             | 40 (9.0) |                |
| CUPi                            |         |                |
| Low risk                        | 224 (50.3) |             |
| Medium risk                     | 164 (36.9) |            |
| High risk                       | 57 (12.8) |                |
| CLIP score                      |         |                |
| 0                               | 57 (12.8) |                |
| 1                               | 86 (19.3) |                |
| 2                               | 105 (23.6) |            |
| 3                               | 96 (21.6) |                |
| 4                               | 64 (14.4) |                |
| 5                               | 34 (7.6) |                |
| 6                               | 3 (0.7) |                |
| BCLC stage                      |         |                |
| A                               | 64 (14.4) |                |
| B                               | 107 (24.0) |            |
| C                               | 251 (56.4) |            |
| D                               | 23 (5.2) |                |
| IL-8 (pg/mL)                    | 74.8 (2.0–1670.5) |        |
| Log IL-8                        |         |                |
| <1.8                            | 207 (46.5) |            |
| ≥1.8                            | 238 (53.5) |            |

(Continued)

Table 2 (Continued)

| Factors                                      | No. (%) | Median (range) |
|----------------------------------------------|---------|----------------|
| Modified inflammation-based index            |         |                |
| 0                                            | 109 (24.5) |          |
| 1                                            | 127 (28.5) |          |
| 2                                            | 123 (27.6) |          |
| 3                                            | 86 (19.3) |              |
| C-reactive protein (mg/L)                    |         |                |
| ≤10                                          | 199 (44.7) |          |
| >10                                          | 246 (55.3) |          |
| First-line treatment                         |         |                |
| Surgical intervention                        | 51 (11.5) |            |
| Percutaneous RFA/ethanol injection           | 28 (6.3) |                |
| LEM/TACE/TAE                                 | 110 (24.7) |           |
| Systemic therapy                             | 85 (19.1) |            |
| Best supportive care                         | 171 (38.4) |          |

**Abbreviations:** AFP, α-fetoprotein; AJCC, American Joint Committee on Cancer; ALT, alanine transaminase; BCLC, Barcelona clinic liver cancer; CLIP, the Cancer of the liver Italian Program; CUPi, the Chinese University Prognostic index; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; LEM, transarterial lipiodol-ethanol mixture; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; TAE, transarterial embolization.

therapy, 85 (19%) had systemic therapy, and 171 (38%) had best supportive care alone. The mean C30 index score was 30.4 (±19.5), and the mean HCC18 index score was 25.1 (±17.1). The median follow-up duration was 30.5 (95% CI = 27.5–33.7) months. The median OS was 8.9 (95% CI = 7.3–10.4) months.

**Correlation between HRQoL and IL-8 level**

The mean IL-8 level was 128.4 (±171.7) pg/ml, and the mean log IL-8 value was 1.84 (±0.51) pg/ml. HRQoL was significantly correlated with log IL-8 level (see Table 4). Log IL-8 had positive and significant correlations with C30 index score, HCC18 index score, QLQ-C30 "fatigue", "nausea and vomiting", "pain", "dyspnea", "insomnia", "appetite loss", "diabetes", and "financial difficulty", QLQ-HCC18 "fatigue", "body image", "jaundice", "nutrition", "pain", "sex life", and "abdominal swelling" (P<0.05). Log IL-8 had a negative and significant correlation with QLQ-C30 "physical functioning", "role functioning", "emotional functioning", "social functioning", and "global QoL". That is, a higher log IL-8 level was correlated with worse HRQoL. The strongest correlations were detected with HCC18 index score, where the Pearson’s correlation coefficient was r = 0.321 (P<0.0001); the corresponding result for C30 index score was 0.306 (P<0.0001); for QLQ-C30 “appetite loss”, r = 0.322 (P<0.0001); for QLQ-C30 “fatigue”, r = 0.311 (P<0.0001); for QLQ-C30 “role functioning”, r = -0.305 (P<0.0001); for QLQ-HCC18 “nutrition”, etc.
The correlations of HRQoL with inflammatory markers were investigated. C30 and HCC18 index scores, as well as the majority of the domains and items in the EORTC QLQ-C30 and QLQ-HCC18, were significantly correlated with IL-8 level and mIBI. These suggest the potential associations between HRQoL and inflammation, and since IL-8 and mIBI have both been previously shown to be prognosticators, it may help explain previous reports.

### Table 3 Health-related QoL characteristics of the 455 HCC patients based on EORTC QLQ-C30 and EORTC QLQ-HCC18 assessment

| QoL variable         | Mean    | ±SD     | Median | Min.  | Max   |
|----------------------|---------|---------|--------|-------|-------|
| **EORTC QLQ-C30**    |         |         |        |       |       |
| Physical functioning | 72.28   | 23.96   | 80.00  | 0.00  | 100.00|
| Role functioning     | 75.06   | 32.18   | 100.00 | 0.00  | 100.00|
| Emotional functioning| 70.45   | 25.52   | 75.00  | 0.00  | 100.00|
| Social functioning   | 77.08   | 24.59   | 83.33  | 0.00  | 100.00|
| Cognitive function   | 68.58   | 30.28   | 66.67  | 0.00  | 100.00|
| Global QoL           | 52.53   | 26.38   | 50.00  | 0.00  | 100.00|
| Fatigue              | 42.56   | 29.81   | 33.33  | 0.00  | 100.00|
| Nausea/vomiting      | 11.01   | 21.28   | 0.00   | 0.00  | 100.00|
| Pain                 | 32.10   | 31.55   | 33.33  | 0.00  | 100.00|
| Dyspnea              | 29.74   | 31.27   | 33.33  | 0.00  | 100.00|
| Insomnia             | 40.90   | 35.87   | 33.33  | 0.00  | 100.00|
| Appetite loss        | 31.84   | 35.62   | 33.33  | 0.00  | 100.00|
| Constipation         | 16.63   | 26.72   | 0.00   | 0.00  | 100.00|
| Diarrhea             | 16.10   | 26.52   | 0.00   | 0.00  | 100.00|
| Financial difficulties| 51.16  | 37.26   | 66.67  | 0.00  | 100.00|
| C30 index score      | 30.40   | 19.45   | 26.52  | 0.00  | 90.37 |
| **EORTC QLQ-HCC18**  |         |         |        |       |       |
| Fatigue              | 34.77   | 25.79   | 33.33  | 0.00  | 100.00|
| Body image           | 25.24   | 22.78   | 16.67  | 0.00  | 100.00|
| Jaundice             | 23.48   | 22.23   | 16.67  | 0.00  | 100.00|
| Nutrition            | 26.88   | 21.40   | 20.00  | 0.00  | 100.00|
| Pain                 | 23.26   | 24.44   | 16.67  | 0.00  | 100.00|
| Fever                | 6.37    | 14.48   | 0.00   | 0.00  | 100.00|
| Sex life             | 28.31   | 34.40   | 0.00   | 0.00  | 100.00|
| Abdominal swelling   | 32.66   | 35.12   | 33.33  | 0.00  | 100.00|
| HCC18 index score    | 25.12   | 17.08   | 21.94  | 0.00  | 87.50 |

Abbreviations: EORTC, European Organization for Research and Treatment of Cancer; HCC, hepatocellular carcinoma; QoL, quality of life.

In summary, patients with higher mIBI score (ie, higher inflammatory status) had worse HRQoL. Additional analyses were conducted using logistic regression, and findings of univariate and multivariate analyses support the above findings (see Tables S3 and S4).

### Discussion
In the present study, the correlations of HRQoL with inflammatory markers were investigated. C30 and HCC18 index scores, as well as the majority of the domains and items in the EORTC QLQ-C30 and QLQ-HCC18, were significantly correlated with IL-8 level and mIBI. These suggest the potential associations between HRQoL and inflammation, and since IL-8 and mIBI have both been previously shown to be prognosticators, it may help explain previous reports.

---

$r=0.317 (P<0.0001)$; and for QLQ-HCC18 “fatigue”, $r=0.306 (P<0.0001)$. Scatter plots for C30 and HCC18 index scores against log IL-8 are shown in Figures 1 and 2, respectively.
in which HRQoL was found to be a significant prognostic factor for survival in HCC patients that was independent of stage and liver function.6–9

C30 and HCC18 index scores were the strongest prognostic HRQoL factors for OS in HCC patients in a previous study;9 the underlying reason has been suggested to be due to their representativeness of all factors within their respective HRQoL instruments.9 In the current analysis, the performance of these two index scores remained better than the majority of individual HRQoL factors. This further supports the representative power of these two index scores. As mentioned previously, the simplicity of a single index score, in contrast to a large collection of scores in an HRQoL instrument, enables convenient utilization of complex HRQoL data for routine clinical use. Since QoL index scores have a significant correlation with IL-8 level and mIBI, we tentatively suggest that the inflammatory status of an individual patient may affect his/her HRQoL.

Although the majority of factors in QLQ-C30 and QLQ-HCC18 have significant correlations with IL-8 level, it is noteworthy that quite a number of these correlations, which were mainly liver-disease related, were only modest. Among the strongest correlations with IL-8 were QLQ-C30 fatigue, QLQ-HCC18 fatigue, QLQ-C30 appetite loss, QLQ-HCC18 nutrition, and QLQ-C30 role functioning. These factors reflect constitutional symptoms, eg, malaise, anorexia, weight loss, and cachexia. Inflammatory response, as represented by IL-8 level, could potentially cause constitutional symptoms, thereby resulting in QoL impairment that was captured by the present study. In other words, the inflammatory status of HCC patients was associated with a specific pattern of HRQoL impairment, predominantly involving adverse effects on constitutional symptoms but not on factors associated with liver disease-related symptoms. When paralleled with molecular findings, traditional HRQoL assessment has gained

| QoL variable | Pearson’s r | P-value |
|--------------|-------------|---------|
| EORTC QLQ-C30 |             |         |
| C30 Physical functioning | –0.275 | <0.0001 |
| C30 Role functioning | –0.305 | <0.0001 |
| C30 Emotional functioning | –0.096 | 0.403 |
| C30 Cognitive functioning | –0.069 | 0.144 |
| C30 Social functioning | –0.244 | <0.0001 |
| C30 Global QoL | –0.25 | <0.0001 |
| C30 Fatigue | 0.311 | <0.0001 |
| C30 Nausea/vomiting | 0.194 | <0.0001 |
| C30 Pain | 0.217 | <0.0001 |
| C30 Dyspnoea | 0.177 | 0.0002 |
| C30 Insomnia | 0.165 | 0.0005 |
| C30 Appetite loss | 0.322 | <0.0001 |
| C30 Constipation | 0.024 | 0.618 |
| C30 Diarrhea | 0.116 | 0.0146 |
| C30 Financial difficulty | 0.208 | <0.0001 |
| C30 index-score | 0.306 | <0.0001 |
| EORTC QLQ-HCC18 |             |         |
| HCC18 Fatigue | 0.306 | <0.0001 |
| HCC18 Body image | 0.267 | <0.0001 |
| HCC18 Jaundice | 0.13 | 0.006 |
| HCC18 Nutrition | 0.317 | <0.0001 |
| HCC18 Pain | 0.164 | 0.0005 |
| HCC18 Fever | 0.089 | 0.0619 |
| HCC18 Sex life | 0.138 | 0.0034 |
| HCC18 Abdominal swelling | 0.29 | <0.0001 |
| HCC18 index-score | 0.321 | <0.0001 |

Abbreviations: EORTC, European Organization for Research and Treatment of Cancer; HCC, hepatocellular carcinoma; HRQoL, health-related quality of life; QoL, quality of life.

Figure 1 Scatter plot of C30 index scores against log IL-8 levels of the 455 HCC patients.

Abbreviation: HCC, hepatocellular carcinoma.

Figure 2 Scatter plot of HCC18 index scores against log IL-8 levels of the 455 HCC patients.

Abbreviation: HCC, hepatocellular carcinoma.
Conclusion
Baseline HRQoL using conventional assessment of EORTC QLQ-C30 and QLQ-HCC18, as well as C30 and HCC18 index scores, significantly correlated with inflammatory indicators (IL-8 level and mIBI) in HCC patients. Among the strongest correlations were those between IL-8 level and the two index scores, as well as HRQoL aspects that represent constitutional symptoms within the EORTC HRQoL instruments. The current findings bring forth insights to traditional HRQoL assessment, and could potentially revolutionize the understanding and utility of HRQoL in HCC patients: pattern recognition within a HRQoL instrument could help to identify patients with more severe inflammatory state.

Author contributions
Leung Li, Winnie Yeo, Stephen L Chan, Frankie Mo, Edwin P Hui, Jane Koh, Allen KC Chan, Nelson LS Tang, Kit F Lee, Paul BS Lai, and Simon CH Yu contributed to the following: substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; drafting the article or revising it critically for important intellectual content; final approval of the version to be published; and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Winnie Yeo provided general supervision to the research group.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
2. Kim UB, Doo CJ, Baek SH, et al. Natural history and prognostic factors of primary hepatocellular carcinoma: study of 70 untreated patients. Korean J Intern Med. 1989;4(2):136–142.
3. Calvet X, Bruix J, Ginés P, et al. Prognostic factors of hepatocellular carcinoma in the West: a multivariate analysis in 206 patients. Hepatology. 1990;12(4 Pt 1):753–760.
4. Pawarode A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol. 1998;21(4):386–391.
5. Okuda K, Ohtsu T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients. Cancer. 1985;56(4):918–928.
6. Yeo W, Mo FK, Koh J, et al. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol. 2006;17(7):1083–1089.
7. Bonnetain F, Pauletti X, Collette S, et al. Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. Qual Life Res. 2008;17(6):831–843.
8. Diouf M, Fillater T, Barbare JC, et al. The added value of quality of life (QOL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. *J Hepatol*. 2013;58(3):509–521.

9. Li L, Mo FK, Chan SL, et al. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data. *BMC Cancer*. 2017;17(1):8.

10. Li L, Yeo W. Value of quality of life analysis in liver cancer: a clinician’s perspective. *World J Hepatol*. 2017;9(20):867–883.

11. Greten TF, Duffy AG, Korangy F. Hepatocellular carcinoma from an immunologic perspective. *Clin Cancer Res*. 2013;19(24):6678–6685.

12. Wan S, Kuo N, Kryczek I, Zou W, Welling TH. Myeloid cells in hepatocellular carcinoma. *Hepatology*. 2015;62(4):1304–1312.

13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144(5):646–674.

14. Hernandez-Gea V, Toftanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. *Gastroenterology*. 2013;144(3):512–527.

15. Arihara F, Mizuokoshi E, Kitahara M, et al. Increase in CD14+HLA-DR+low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. *Cancer Immunol Immunother*. 2013;62(8):1421–1430.

16. Chew V, Tow C, Teo M, et al. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. *J Hepatol*. 2010;52(3):370–379.

17. Jang JW, Oh BS, Kwon JH, et al. Serum IL-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. *Cytokine*. 2012;60(3):686–693.

18. Cho HJ, Kim SS, Ahn SJ, et al. Low serum IL-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment. *Cytokine*. 2015;73(2):245–252.

19. Qiu X, Wang X, Song Y, Chen L. Plasma level of IL-35 as an independent prognostic indicator in hepatocellular carcinoma. *Dig Dis Sci*. 2016;61(12):3513–3521.

20. Chen ZY, Wei W, Guo ZX, et al. Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts. *Br J Cancer*. 2014;110(3):733–740.

21. Welling TH, Fu S, Wan S, Zou W, Marrero JA. Elevated serum IL-8 is associated with the presence of hepatocellular carcinoma and independently predicts survival. *Cancer Invest*. 2012;30(10):689–697.

22. Kim SS, Cho HJ, Won JH, et al. IL-8 level as a prognostic marker in patients with hepatitis B virus-associated hepatocellular carcinoma treated with transarterial chemoembolization. *Cytokine*. 2015;76(2):449–457.

23. Chan SL, Chan AW, Chan AK, et al. Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. *Liver Int*. 2017;37(2):280–289.

24. Sterbny Eilard M, Hagström H, Mortensen KE, et al. Quality of life as a prognostic factor for survival in hepatocellular carcinoma. *Liver Int*. 2018;38(5):885–894.

25. Oliveira Miranda D, Soares de Lima TA, Ribeiro Azevedo L, Feres O, Ribeiro da Rocha JI, Pereira-da-Silva G. Proinflammatory cytokines correlate with depression and anxiety in colorectal cancer patients. *Biomed Res Int*. 2014;2014(5):1–5.

26. Kao SC, Vardy J, Harvie R, et al. Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. *Support Care Cancer*. 2013;21(3):697–705.

27. Lynch Kelly D, Lyon DE, Ameringer SA, Elswick RK. Symptoms, cytokines, and quality of life in patients diagnosed with chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. *Oncol Nurs Forum*. 2015;42(3):265–275.

28. Panju AH, Danesh A, Minden MD, Kelvin DJ, Alibhai SM. Associations between quality of life, fatigue, and cytokine levels in patients aged 50+ with acute myeloid leukemia. *Support Care Cancer*. 2009;17(5):539–546.

29. Paulsen O, Laird B, Aas N. The relationship between pro-inflammatory cytokines and pain, appetite and fatigue in patients with advanced cancer. *PLoS One*. 2017;12(5):e0177620.

30. Chiba F, Soda K, Yamada S, et al. The importance of tissue environment surrounding the tumor on the development of cancer cachexia. *Int J Oncol*. 2014;44(1):177–186.

31. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst*. 1993;85(5):365–376.

32. Blazey JM, Currie E, Zee BC, et al. Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. *Eur J Cancer*. 2004;40(16):2439–2444.

33. Oh B, Butow P, Mullan B, et al. Impact of medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial. *Ann Oncol*. 2010;21(3):608–614.

34. Sprod LK, Janelinsins MC, Palesh OG, et al. Health-related quality of life and biomarkers in breast cancer survivors participating in tai chi chuan. *J Cancer Surviv*. 2012;6(2):146–154.

35. Hojan K, Kwiatkowska-Borowczyk E, Leporowska E, Milecki P. Inflammatory markers in malignant pleural mesothelioma. *Support Care Cancer*. 2014;2014(5):1–5.

36. Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. *Phytother Res*. 2014;28(10):1461–1467.
## Supplementary materials

### Table S1 Univariate logistic regressions of HRQoL variables for log IL-8 ≥1.8

| QoL variable       | OR   | 95% CI for OR | P-value |
|--------------------|------|---------------|---------|
| C30 Physical functioning | 0.981 | 0.972–0.989 | <0.0001 |
| C30 Role functioning   | 0.983 | 0.977–0.990 | <0.0001 |
| C30 Emotional functioning | 0.995 | 0.987–1.002 | 0.1536 |
| C30 Cognitive functioning | 0.995 | 0.998–1.003 | 0.2292 |
| C30 Social functioning   | 0.987 | 0.980–0.993 | <0.0001 |
| C30 Global QoL         | 0.982 | 0.974–0.989 | <0.0001 |
| C30 Fatigue             | 1.020 | 1.013–1.027 | <0.0001 |
| C30 Nausea/vomiting     | 1.020 | 1.009–1.030 | 0.0002 |
| C30 Pain                | 1.014 | 1.008–1.020 | <0.0001 |
| C30 Dyspnoea            | 1.009 | 1.003–1.015 | 0.0054 |
| C30 Insomnia            | 1.009 | 1.003–1.014 | 0.0016 |
| C30 Appetite loss       | 1.017 | 1.011–1.023 | <0.0001 |
| C30 Constipation        | 1.001 | 0.994–1.008 | 0.6989 |
| C30 Diarrhea            | 1.009 | 1.002–1.016 | 0.0178 |
| C30 Financial difficulty| 1.010 | 1.005–1.015 | 0.0002 |
| C30 index-score         | 1.030 | 1.019–1.041 | <0.0001 |
| HCC18 Fatigue           | 1.024 | 1.015–1.032 | <0.0001 |
| HCC18 Body image        | 1.020 | 1.011–1.030 | <0.0001 |
| HCC18 Jaundice          | 1.009 | 1.000–1.017 | 0.0498 |
| HCC18 Nutrition         | 1.032 | 1.021–1.043 | <0.0001 |
| HCC18 Pain              | 1.011 | 1.003–1.019 | 0.0071 |
| HCC18 Fever             | 1.020 | 1.004–1.035 | 0.0107 |
| HCC18 Sex life          | 1.004 | 0.998–1.009 | 0.1723 |
| HCC18 Abdominal swelling| 1.014 | 1.008–1.020 | <0.0001 |
| HCC18 Index-score       | 1.034 | 1.021–1.047 | <0.0001 |

**Abbreviations:** HCC, hepatocellular carcinoma; HRQoL, health-related quality of life; QoL, quality of life.

### Table S2 Multiple logistic regressions of HRQoL variables for log IL-8 ≥1.8

| QoL variable       | OR   | 95% CI for OR | P-value |
|--------------------|------|---------------|---------|
| C30 Fatigue        | 1.012 | 1.004–1.021 | 0.0055 |
| C30 Appetite loss  | 1.011 | 1.004–1.019 | 0.0021 |
| HCC18 Nutrition    | 1.022 | 1.008–1.035 | 0.0013 |
| HCC18 Fatigue      | 1.013 | 1.002–1.023 | 0.0163 |

**Abbreviations:** HCC, hepatocellular carcinoma; HRQoL, health-related quality of life; QoL, quality of life.

### Table S3 Univariate logistic regressions of HRQoL variables for mIBI 2–3

| QoL variable          | OR   | 95% CI for OR | P-value |
|-----------------------|------|---------------|---------|
| C30 Physical functioning | 0.969 | 0.960–0.978 | <0.0001 |
| C30 Role functioning   | 0.977 | 0.971–0.984 | <0.0001 |
| C30 Emotional functioning | 0.996  | 0.988–1.003 | 0.2282 |
| C30 Cognitive functioning | 0.993  | 0.985–1.000 | 0.0669 |
| C30 Social functioning | 0.982 | 0.975–0.988 | <0.0001 |
| C30 Global QoL        | 0.980 | 0.972–0.987 | <0.0001 |
| C30 Fatigue           | 1.024 | 1.017–1.031 | <0.0001 |
| C30 Nausea/vomiting   | 1.027 | 1.016–1.038 | <0.0001 |
| C30 Pain              | 1.017 | 1.010–1.023 | <0.0001 |
| C30 Dyspnoea          | 1.012 | 1.005–1.018 | 0.0003 |
| C30 Insomnia          | 1.009 | 1.003–1.014 | 0.0013 |
| C30 Appetite loss     | 1.019 | 1.013–1.025 | <0.0001 |
| C30 Constipation      | 1.002 | 0.995–1.009 | 0.5740 |
| C30 Diarrhea          | 1.010 | 1.002–1.017 | 0.0093 |
| C30 Financial difficulty | 1.011 | 1.005–1.016 | <0.0001 |
| C30 index-score       | 1.037 | 1.026–1.049 | <0.0001 |
| HCC18 Fatigue         | 1.027 | 1.019–1.036 | <0.0001 |
| HCC18 Body image      | 1.030 | 1.020–1.039 | <0.0001 |
| HCC18 Jaundice        | 1.008 | 0.999–1.016 | 0.0818 |
| HCC18 Nutrition       | 1.033 | 1.023–1.044 | <0.0001 |
| HCC18 Pain            | 1.015 | 1.007–1.023 | 0.0003 |
| HCC18 Fever           | 1.019 | 1.005–1.034 | 0.0080 |
| HCC18 Sex life        | 1.007 | 1.001–1.012 | 0.0196 |
| HCC18 Abdominal swelling | 1.020 | 1.014–1.026 | <0.0001 |
| HCC18 Index-score     | 1.044 | 1.031–1.057 | <0.0001 |

**Abbreviations:** HCC, hepatocellular carcinoma; HRQoL, health-related quality of life; mIBI, modified inflammation-based index; QoL, quality of life.

### Table S4 Multiple logistic regressions of HRQoL variables for mIBI 2–3

| QoL variable          | OR   | 95% CI for OR | P-value |
|-----------------------|------|---------------|---------|
| C30 Physical functioning | 0.984 | 0.973–0.996 | 0.0074 |
| C30 Role functioning   | 0.989 | 0.981–0.998 | 0.0150 |
| C30 Appetite loss      | 1.010 | 1.004–1.017 | 0.0028 |
| HCC18 Abdominal swelling | 1.012  | 1.005–1.019 | 0.0013 |
| HCC18 Nutrition        | 1.015 | 1.001–1.028 | 0.0327 |
| HCC18 Fatigue          | 1.012 | 1.001–1.023 | 0.0347 |

**Abbreviations:** HCC, hepatocellular carcinoma; HRQoL, health-related quality of life; mIBI, modified inflammation-based index; QoL, quality of life.

---

Cancer Management and Research

**Publish your work in this journal**

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journal

Cancer Management and Research 2019:11

submit your manuscript | www.dovepress.com 2727